KR20220148881A - 진균 감염 치료에서의 화합물의 용도 - Google Patents

진균 감염 치료에서의 화합물의 용도 Download PDF

Info

Publication number
KR20220148881A
KR20220148881A KR1020227034025A KR20227034025A KR20220148881A KR 20220148881 A KR20220148881 A KR 20220148881A KR 1020227034025 A KR1020227034025 A KR 1020227034025A KR 20227034025 A KR20227034025 A KR 20227034025A KR 20220148881 A KR20220148881 A KR 20220148881A
Authority
KR
South Korea
Prior art keywords
spp
compound
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227034025A
Other languages
English (en)
Korean (ko)
Inventor
카렌 조이 쇼
마이클 호지스
Original Assignee
앰플릭스 파마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앰플릭스 파마슈티컬스, 인크. filed Critical 앰플릭스 파마슈티컬스, 인크.
Publication of KR20220148881A publication Critical patent/KR20220148881A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227034025A 2020-03-04 2021-03-02 진균 감염 치료에서의 화합물의 용도 Ceased KR20220148881A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985274P 2020-03-04 2020-03-04
US62/985,274 2020-03-04
PCT/US2021/020471 WO2021178406A1 (en) 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections

Publications (1)

Publication Number Publication Date
KR20220148881A true KR20220148881A (ko) 2022-11-07

Family

ID=77612811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034025A Ceased KR20220148881A (ko) 2020-03-04 2021-03-02 진균 감염 치료에서의 화합물의 용도

Country Status (11)

Country Link
US (2) US12521406B2 (https=)
EP (1) EP4114405A4 (https=)
JP (1) JP2023516648A (https=)
KR (1) KR20220148881A (https=)
CN (1) CN115515599A (https=)
AU (1) AU2021230529B2 (https=)
BR (1) BR112022017653A2 (https=)
CA (1) CA3174065A1 (https=)
IL (1) IL296093A (https=)
MX (1) MX2022010804A (https=)
WO (1) WO2021178406A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187268A1 (en) * 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CN116687929B (zh) * 2023-06-16 2026-04-28 山东省妇幼保健院 血根碱在制备防治临床罕见真菌相关感染性疾病药物中的应用
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
CN119915948B (zh) * 2025-04-02 2025-07-08 天津辰欣药物研究有限公司 一种小分子真菌肌醇酰基转移酶1抑制剂原料药中致突变杂质的分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2345641A1 (en) 2009-12-29 2011-07-20 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives
EP2636409A1 (en) * 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
IL275121B2 (en) * 2017-12-07 2025-11-01 Amplyx Pharmaceuticals Inc Heterocycle substituted pyridine derivative antifungal agents
WO2020047510A1 (en) 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CA3187268A1 (en) 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Also Published As

Publication number Publication date
US20260102419A1 (en) 2026-04-16
CA3174065A1 (en) 2021-09-10
AU2021230529A1 (en) 2022-09-29
NZ792042A (en) 2025-09-26
JP2023516648A (ja) 2023-04-20
AU2021230529B2 (en) 2024-09-05
EP4114405A4 (en) 2024-03-13
WO2021178406A1 (en) 2021-09-10
US12521406B2 (en) 2026-01-13
EP4114405A1 (en) 2023-01-11
US20230102036A1 (en) 2023-03-30
CN115515599A (zh) 2022-12-23
BR112022017653A2 (pt) 2022-10-18
MX2022010804A (es) 2023-01-16
IL296093A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
US12521406B2 (en) Use of compounds in the treatment of fungal infections
JP2017533944A (ja) Ｔｌｒ阻害剤及びブルトンチロシンキナーゼ阻害剤の併用
JP7793681B2 (ja) 真菌感染症を処置するための化合物および方法
WO2016131100A1 (en) Methods of treating infectious diseases
TWI289456B (en) Antibiotic pharmaceutical compositions and kits comprising azithromycin and a p-glycoprotein inhibitor
US20230233576A1 (en) Eclitasertib for use in treating conditions involving systemic hyperinflammatory response
CN110494140A (zh) 用于自闭症谱系障碍药物治疗的方法
TW202333731A (zh) 用於治療癌症之VCP/p97抑制劑
AU2021293911B2 (en) Compounds and methods for treating fungal infections
RU2805930C1 (ru) Использование соединений при лечении грибковых инфекций
HK40086224A (zh) 化合物在真菌感染的治疗中的用途
US20240245666A1 (en) Dosing regimens
RU2824066C1 (ru) Соединения и способы для лечения грибковых инфекций
HK40085944A (en) Compounds and methods for treating fungal infections
US20240366599A1 (en) Human efficacious dose and dosage schedule of spr720
TWI920017B (zh) 用於治療真菌感染之化合物及方法
US20250302821A1 (en) Synergistic antifungal composition and method
US20210401806A1 (en) Compositions and methods for treatment of vaginal infections
HK40050392A (en) Compounds and methods for treating fungal infections

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601